<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612906</url>
  </required_header>
  <id_info>
    <org_study_id>2022-Renal nerve denervation</org_study_id>
    <nct_id>NCT05612906</nct_id>
  </id_info>
  <brief_title>Renal Nerve Denervation(RDN) and Renal Function</brief_title>
  <official_title>Effect of RDN on Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhengrong Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Xiamen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current studies have found the efficacy of RDN in the treatment of hypertension, however, the&#xD;
      safety of RDN in renal function is still lacking. Therefore, the investigators are aimed to&#xD;
      study the effect of RDN on renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of serum creatinine and urea nitrogen before and after RDN operation</measure>
    <time_frame>Baseline,1week/1 month/6months after RDN operation</time_frame>
    <description>Serum creatinine(umol/L, ammonia iminohydrolase assay)and urea nitrogen(umol/L, urease methods) were obtained by blood test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of glomerular filtration rate before and after RDN operation</measure>
    <time_frame>Baseline, 6months after RDN operation</time_frame>
    <description>Glomerular filtration rate(ml/min) were obtained by ECT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of RDN operation on renal artery</measure>
    <time_frame>Baseline, 6months after RDN operation</time_frame>
    <description>Renal arteries were observed by CT angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/serum creatinine ratio change before and after RDN operation</measure>
    <time_frame>Baseline,1week/1 month/6months after RDN operation</time_frame>
    <description>Urinary protein (mg/L, PRM assay) were tested by urine test.Serum creatinine(umol/L, ammonia iminohydrolase assay) were obtained by blood test.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Effects of RDN on Renal Function</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with refractory hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.18&lt;age≤75 years; 2.clinic blood pressure ≥ 140/90 mmHg or 24-hour ambulatory blood&#xD;
        pressure monitoring average blood pressure ≥ 135/85 mmHg after taking 3 or more&#xD;
        antihypertensive drugs for more than 4 weeks; 3.essential hypertension, renal parenchymal&#xD;
        hypertension, or hypertension patients who are willing to receive RDN ; 4.who signed&#xD;
        informed consent and were approved by the Ethics Committee of the First Affiliated Hospital&#xD;
        of Xiamen University.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women or lactating patients;&#xD;
&#xD;
               -  identified secondary hypertension or Pseudo hypertension;&#xD;
&#xD;
                    -  whose renal arteries were unsuitable for ablation&#xD;
&#xD;
                         -  obvious bleeding tendency and blood system diseases;&#xD;
&#xD;
                              -  malignant tumors or end-stage diseases; ⑥Severe peripheral&#xD;
                                 vascular disease, abdominal aortic aneurysm; ⑦A history of the&#xD;
                                 acute coronary syndrome within two weeks; ⑧acute or severe&#xD;
                                 systemic infection; ⑨drug or alcohol dependence or refusal to sign&#xD;
                                 informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhengrong Huang, M.D.</last_name>
    <phone>+8613606028353</phone>
    <email>huangzhengrong@xmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>zhengrong Huang</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengrong Huang, M.D.</last_name>
      <phone>+8613606028353</phone>
      <email>huangzhengrong@xmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>August 18, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Xiamen University</investigator_affiliation>
    <investigator_full_name>Zhengrong Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

